Blood Transfusion Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Blood Transfusion Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Blood Transfusion Devices Market is expected to register a CAGR of 5.7% during the forecast period (2022 - 2027).

Globally, the COVID-19 pandemic has caused overwhelming pressure on everyone around the world. Not only the public healthcare system is overloaded with patients, but also the public is panicked and restricted in their mobility, and their daily life is completely changed. According to a research study by Jennifer N. S. Leung et al., published in the International Society of Blood Transfusion in April 2020, in China, the first 3 months of the year 2020 were painful and stressful in managing both blood safety and supply. Furthermore, the blood transfusion service encounters significant difficulties to sustain a safe blood supply. With preventive measures, the public and donors have restored their confidence that blood donation is safe. However, as mobility restrictions continue to be enforced, there will be an ongoing challenge to collect sufficient blood to meet patients' transfusion demands. According to a research study by Andre Loua et al., published in the International Society of Blood Transfusion (ISBT) in December 2020, like all regions in the world, the African region also faced socio-economic disruption due to the COVID-19 pandemic. It makes a significant impact on health service delivery. Overall, it was revealed through the survey that the safe blood supply and demand were at risk since there was a decrease in these activities in most of the respondent countries in the region, especially at the beginning of the COVID-19 pandemic. Therefore, the COVID-19 pandemic has led to a reduction in blood-related activities in the African region, including supply and demand.

Some of the factors that are driving the market growth include the increasing number of surgical procedures, increasing accidents and trauma cases, a rise in the number of blood disorders, and technological development.

The most commonly performed surgeries that require blood transfusion include cardiovascular procedures, C-section procedures, and trauma and accident injuries. As per the World Health Organization updates in 2021, worldwide cesarean section rates have risen from around 7% in 1990 to 21% today, and are projected to continue increasing over this current decade. If this trend continues, by 2030 the highest rates are likely to be in Eastern Asia (63%), Latin America and the Caribbean (54%), Western Asia (50%), Northern Africa (48%) Southern Europe (47%) and Australia and New Zealand (45%). Thus, the growing number of surgical procedures is likely to increase the demand for blood transfusion devices.

Leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) are types of cancer that can affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. It was observed that apheresis technology has been used, to reduce the number of white cells, until they can be controlled by other medications. For instance, leukemia is characterized by an abnormal increase of white blood cells making the blood thick.

According to the Leukemia & Lymphoma Society (LLS), approximately every three minutes, one person in the United States is diagnosed with blood cancer. An estimated combined total of 186,400 people in the United States are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021. New cases of leukemia, lymphoma, and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases that will be diagnosed in the United States in 2021.

The market players are adopting various strategies such as product launches, developments, collaborations, partnerships, and expansions to increase market share. For instance, in May 2022, Vitestro launched an autonomous blood drawing device at the annual meeting of the Netherlands Society for Clinical Chemistry and Laboratory Medicine (NVKC) in Rotterdam. Vitestro’s device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. Such launches are likely to drive market growth during the forecast year.

In addition, in January 2020, Fresenius Kabi inaugurates a EUR 30 million expansion of the transfusion and apheresis disposables plant in the Dominican Republic. The company undertook the expansion to meet the rising demand for these high-quality disposables. Moreover, Vitestro plans to begin a pivotal clinical trial of the new device for regulatory approval in Europe in 2023 and expects to bring it to the European market in 2024.

However, factors such as stringent regulatory framework and high costs associated with the handling of blood and its components are expected to impede the market growth over the forecast period.

Key Market TrendsThe Pathogen Reduction System is Expected to Witness a Healthy Growth Rate Over the Forecast Period

The pathogen reduction system segment of the blood transfusion market is believed to witness healthy growth over the forecast period. The demand for a pathogen reduction system is growing with the emergence of a cost-effective and innovative solution to inactivate or reduce the risk of infection. For instance, the INTERCEPT Blood System from Cerus Corporation which is effective in reducing the risk of transfusion-transmitted infections (TTI), and pathogen reduction for platelet components provides a solution to blood centers and hospital clients that ultimately benefits patients who need it most.

Blood transfusion is an almost routine medical procedure that is commonly life-saving, repleting blood losses due to surgery, injury, and chemotherapy. The rapid spread of COVID-19 has challenged healthcare systems to re-organize the management of patients in a short period. COVID-19 spreads mainly through droplets during close contact with a symptomatic patient and may be airborne during direct exposure to the virus such as through endotracheal intubation, mechanical ventilation, bronchoscopy, open suction, tracheostomy, and cardiopulmonary resuscitation.

According to a research study by Josiane Bassil et al., published in Future Sci OA Journal in September 2020, the COVID-19 pandemic has impacted medical care among these patients as blood donations were limited during the lockdown period. Mobility constraints have reduced the number of blood donations and supplies and the safety of blood transfusion was a matter of considerable concern.

Furthermore, there was a reduction in several blood transfusion procedures due to the presence of plasmatic SARS-CoV-2 RNA in 15% of symptomatic patients with COVID-19 as reported by the American Association of Blood Banks in October 2020, and the possibility of blood transmission as reported in vertical mother-to-fetus transmission in pregnant COVID-19-infected women.

According to a research study by Sudhir Rama Varma et al., published in the Journal of International Society of Preventive and Community Dentistry in November 2020, the study results found that during the COVID-19 pandemic, various technologies used to eradicate pathogens found in routine blood products, used in oral and periodontal surgical procedures. The use of pathogen reduction technology might offer a ray of light to contain the spread among dental treatment procedures.

The pathogen reduction system is used primarily for the treatment of leukostasis, caused by elevated white blood count in leukemia. It is also used in severe rheumatoid arthritis, to reduce the risk of antibody-mediated rejection of organs during, systemic lupus, Goodpasture syndrome, polymyositis or dermatomycosis, and preeclampsia and eclampsia in pregnancy. Moreover, According to new research from the World Health Organization (WHO) in June 2021, caesarean section use continues to rise globally, now accounting for more than 1 in 5 (21%) of all childbirths. This number is set to continue increasing over the coming decade, with nearly a third (29%) of all births likely to take place by caesarean section by 2030. Therefore the increasing caesarean section worldwide the growth of the segment is expected to surge over the forecast period.

The market players are offering pathogen reduction systems with different technologies. For instance, the Mirasol Pathogen Reduction Technology (PRT) system developed by Terumo’s Blood and Cell Technologies Company (Terumo BCT) uses UV light and riboflavin (vitamin B2) to inactivate a broad range of pathogens, including bacteria, viruses such as HIV, parasites such as malaria, and white blood cells in blood products, reducing the risks of disease transmission and side effects from blood transfusions.

In December 2021, Health Canada approved the use of Cerus INTERCEPT pathogen inactivation technology to produce pathogen-reduced pooled platelet components at Canadian Blood Services. This approval paved the way for Canadian Blood Services to manufacture its first pathogen-inactivated blood component: pathogen-reduced platelets. Thus, owing to the above-mentioned factors it is expected to drive the segment growth over the forecast period.

North America is Expected to Hold a Significant Share in the Market Over the Forcasted Period

Some of the factors that are driving the market growth in North America region include increasing number of trauma cases and surgical procedures, technological advancements, and presence of key market players.

In May 2020, the “The Fight Is In Us” campaign was launched, to recruit COVID-19 survivors within two months of their recovery to donate their plasma at licensed blood and plasma donor centers and also to ensure that their blood plasma contains a robust enough concentration of antibodies to have a positive effect on donating the plasma to another COVID-19 patient. The coalition was offered at more than 1,500 locations at which COVID-19 survivors can choose to donate. This campaign shows positive impact on the market growth as it has suddenly increased the number of apheresis being done at centers and hospitals by creating the awareness.

In addition, in May 2020, the Department of Defense in United States begun an effort to collect 8,000 donated units of plasma from patients who have recovered from COVID-19 to support the development of an effective treatment against the disease. This effort has given rise to the adoption of plasmapheresis devices and disposables in the United States.

According to the Terry Fox Research Institute, there is an estimated 21,700 people will be diagnosed with blood cancers in Canada in 2019. These cancers affect people of all ages, and survival rates are highly dependent on the type of blood cancer a person is diagnosed with. It is estimated that 7,500 Canadians die from blood cancers, making them the third leading cause of cancer-related death in the country.

Increasing number of surgical procedures is likely to drive the market growth. For instance, as per the 2021 updates of The Centers for Disease and Prevention (CDC) approximately 600,000 hysterectomies are performed in the United States each year. Moreover, according to the American College of Obstetricians and Gynecologists (ACOG) updates in 2020, about a third of all women will have a hysterectomy by the age of 60. These statistics also indicate the high requirement for blood transfusion devices.

In May 2021, Cerus Corporation announced its contract with Canadian Blood Services for the INTERCEPT Blood System for Platelets. The Intercept Blood System for platelets is intended for the ex vivo treatment and storage of platelet components. The system is used to inactivate a broad range of pathogens, including viruses, bacteria, and protozoan parasites, thus reducing the risk of transfusion-transmitted infections (TTI). Thus, owing to above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The Blood Transfusion Devices Market is moderately competitive. However, with technological advancements and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with cost-effective pricing. Some of the market players include Terumo Corporation, Ecomed Solutions, LLC., Kawasumi Laboratories, Inc., Becton Dickinson and Company, B. Braun Melsungen AG., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.